Endpoints News – The biopharma world is here

SUBSCRIBE

top stories

First place finish: Eli Lilly just moved to franchise leader with their second migraine drug OK in 1 year

2 days ago

UPDATED: Pfizer takes aim at a flagship franchise at Sanofi and Regeneron — and scores a few direct hits

20 hours ago

HR violation pushes Revance co-founder out, vaulting former Zeltiq chief to the helm

3 hours ago

US mulls tariffs on Swiss drug exports, weighing on Novartis and Roche – report

2 hours ago

Latest

FDA requests additional time for Flexion's sNDA; Genentech releases data for PhIII study of Rituxan

2 hours ago

BridgeBio drops bid to reclaim Eidos after directors spurn 3 offers

3 hours ago

In-house FDA review flags a suspicious imbalance in deaths as Shionogi hunts an OK for antibiotic

3 hours ago

A predator's world? Top analyst sees the 'haves' and the 'haven'ts' diverge as biotech bubbles form — and collapse

4 hours ago

Cell therapy startup raises $16 million to fund its quest for the Holy Grail in regenerative medicine

5 hours ago

Eyeing $86M, Galera leads a pack of three modest biotech IPOs pushing past high profile stumbles

6 hours ago

see latest stream

People

Microcap Aridis recruits Takeda vet Paul Mendelman to steer late-stage antibody programs in infectious diseases

3 days ago

Roche vice-chair: Let's repair the damage that short-term profit drive has done to the planet

3 days ago

Flemming Ørnskov takes on a new challenge, driving a $10B dermatology spinout with some big plans for growth

4 days ago

Startups

'We're ripe': Cygnal draws the curtain on Flagship's latest bet on exoneural biology — and $65M in cash

6 days ago

Ness Bermingham looks to lead the wave of RNA editing at new Atlas upstart Korro Bio

Last week

Antibody research graduates from a top Oxford lab into the biotech world — with $34M to fund R&D work

Last week

Deals

AbbVie uncoupling costs Reata $330M in cold, hard cash

4 days ago

Neglected on Wall Street, little Stealth Bio finds an affluent chum with $30M in cash and high hopes for their PhIII ...

4 days ago

Parexel embraces real world evidence, enlisting Datavant to drill it into CRO workflow

4 days ago

IPOs

ARCH, SoftBank-backed Vir Biotechnology underwhelms with $143 million IPO

3 days ago

Wall Street trims cancer drug developer BioNTech's unicorn valuation

4 days ago

We’ll see this week if the public markets’ love affair with biotech unicorns is still running hot — or not

Last week

Premium storiesSee all

Court green-lights Clovis case after detailing evidence the board ‘ignored red flags’ on false safety and ...

3 days ago

‘There are moments’: Sanofi’s new CEO is thinking through the R&D strategy — and oncology will be key

Last week

Biotechs are spending record sums on R&D — should that worry you at least a little?

3 weeks ago

A microcap biotech salves old wounds with positive PhII report on status epilepticus, but plenty of questions remain

3 weeks ago

Don't missSee all

Long term data echo safety profile of Gilead, Galapagos' potential blockbuster JAK inhibitor

3 days ago

Bill Gates backs Ginkgo Bioworks' $350M raise to fuel the buzzy synthetic biology 'revolution'

4 days ago

UCB bags a rival to Soliris in $2.1B buyout deal — but will an increasingly vigilant FTC sign off?

4 days ago

The new top 20 pharma list: Takeda jumps on, Biogen pushed out — and more big changes are on the way

5 days ago

Peer review See all

Oct

11

Zosano Pharma CEO passes baton down to successor; James Sapirstein takes the helm at AzurRx

Oct

4

Atlas-backed Dyne taps Joshua Brumm as CEO; Sekar Kathiresan woos cardiologist to gene editing startup

Sep

27

NASH hopeful Genfit promotes Dean Hum to president; Immune Therapeutics CEO passes baton to successor

Sep

20

Chris Roberts jumps back into biotech with CSO gig at Black Diamond; Troubled Five Prime appoints interim CEO

Sep

13

Alex Arfaei trades his analyst's post for a new role as biotech VC; Sanofi vet heads to Vifor

R&D channel feed

6 hours ago

UPDATED: Pelosi drug pricing bill promises savings, but could gag R&D — CBO analysis

The Democrats' drug pricing bill — unveiled by Speaker Nancy Pelosi last month — could save Medicare spending by $345 billion over a seven-year period, a new analysis suggests. But the ...

READ MORE

Ex-AbbVie partner Principia posts encouraging PhII results for its BTK-inhibitor

3 days ago

J&J hands off non-opioid painkiller to an upstart in the race for next-gen analgesics

4 days ago

latest in R&D

Researchers find 15% of trials could be replicated using real world data

3 days ago

Shionogi celebrates antibiotic win in pneumonia just ahead of its date with FDA regulators

5 days ago

Partner Bayer pushes Ionis' antithrombotic drug into mid-stage development

5 days ago

A new player is taking the field in a push for a hemophilia A gene therapy, and it’s a big one

5 days ago

Rare disease clinical trials: FDA awards $15M in grants

5 days ago

see latest stories

Pharma channel feed

3 days ago

In reversal, NICE backs Rubraca after Clovis agrees to a price cut

NICE has changed its mind, agreeing to cautiously endorse Clovis Oncology's Rubraca after the drugmaker agreed to cut its price — about two months after the UK cost-effectiveness agency's ...

READ MORE

Drug price hikes, without justifiable new evidence of benefit — ICER analysis

6 days ago

Differin maker Galderma wins FDA approval for a new retinoid for acne

Last week

latest in Pharma

J&J poaches Bayer exec Jim Swanson as chief information officer

Last week

King Keytruda: Merck's PD-1 star scores #1 position and $22B+ prediction in another top 10 blockbuster list for 2025

Last week

Pharma to blame for impeachment woes? Yep, President Trump just suggested that about America's least favorite industry

Last week

Gilead scores PrEP approval for Descovy — kicking off marketing push before Truvada generics swarm

Last week

In an unusual move, ICER rescinds draft report on JAK drugs for rheumatoid arthritis to revise its modeling approach

Last week

see latest stories